Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70244 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Hans Johnson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digital Health and Care, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Weight Reduction Programs. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
We evaluated the weight loss efficacy and safety of a national digital weight loss service (DWLS) and explored associations between digital engagement and outcomes in adults prescribed dual GIP/GLP‐1RA and GLP‐1RA. Materials and Methods We conducted a retrospective longitudinal cohort analysis of adults prescribed dual GIP/GLP‐1RA and GLP‐1RA between August 2024 and July 2025 within the Voy DWLS in the United Kingdom (UK). Digitally engaged patients met all three criteria: (i) ≥1 coaching session; (ii) weekly weight logging (≥4/month); and (iii) ≥1 additional in‐app interaction. Weight‐loss trajectories were modelled using mixed models for repeated measures (MMRM). Kaplan–Meier methods and Cox models examined time to attain weight loss thresholds (≥5, ≥10, ≥15, ≥20, ≥25%). Safety events were summarised as rates per 1000 patient‐months with 95% CIs.
Results
The cohort included 106 653 adults (mean age 42.3 ± 12.7 years; 77.9% female; baseline BMI 35.2 ± 6.2 kg/m 2 ). Whilst 79.7% ( n = 84 955) used the digital application, 5.7% ( n = 6086) met maximal engagement, with 100 567 classed as not engaged. Across 11 months, engaged patients achieved greater adjusted weight loss than not engaged (21.5% [95% CI −22.0 to −21.1] vs. 17.0% [−17.2 to −16.8]; absolute difference 4.5 percentage points; p < 0.001). Kaplan–Meier analyses showed consistently higher likelihood of milestone attainment for engaged participants (≥5%: HR 1.42, 95% CI 1.38–1.46; ≥10%: HR 1.46, 1.41–1.52; ≥15%: HR 1.53, 1.45–1.61; ≥20%: HR 1.62, 1.50–1.75; ≥25%: HR 1.86, 1.64–2.10; all p < 0.001). Safety analyses over 290 050 patient‐months showed incidence 1.57 per 1000 patient‐months, with no excess risk in engaged groups (IRR 0.83, 95% CI 0.60–1.15).
Conclusions
Digital engagement was associated with 4.5 percentage points greater weight loss (21.5% vs. 17.0%), faster milestone achievement, and comparable safety profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Digital Health and Care, University of Bristol, Bristol, UK.
- Department of Education, University of Oxford, Oxford, UK.
- Department of Clinical Research, Voy, Menwell Ltd, London, UK.
- Department of Surgery & Cancer, Imperial College London, London, UK.
- EGA Institute for Women's Health, University College London, London, UK.
ORCID-Profile: Hans Johnson
Zitieren
APA
Johnson, H., Clift, A. K., Reisel, D., & Huang, D. R. (2026). Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70244
Vancouver
Johnson H, Clift AK, Reisel D, Huang DR. Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70244
BibTeX
@article{Johnson2026,
author = {Johnson, Hans and Clift, Ashley Kieran and Reisel, Daniel and Huang, David R},
title = {Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70244}
}
EUVIMED